Physician profile
Peter A Kringstein
NPI 1134124456
$1,298.04
in general payments reported to CMS, 2019-2025
15 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.07 · 2022: $221 · 2023: $196 · 2024: $327 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,063.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $270.21 | 2022-2025 | |
| Edwards Lifesciences Corporation | $177.75 | 2024-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $175.23 | 2023-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $160.77 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.24 | 2022-2025 | Jardiance |
| Pfizer INC. | $79.22 | 2023-2025 | |
| Amgen INC. | $70.53 | 2022-2024 | Repatha |
| Boston Scientific Corporation | $39.44 | 2025 | Watchman |
| Bridgebio Pharma, INC. | $38.99 | 2025 | Attruby |
| Inspire Medical Systems, INC. | $35.14 | 2024-2025 | Inspire |
| Cvrx, INC. | $33.74 | 2023 | Barostim Neo System |
| Abbott Laboratories | $19.59 | 2022 | |
| Merck Sharp & Dohme LLC | $15.29 | 2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $13.07 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $12.83 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Kringstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.